Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom

Thrombosis Research
A GasmiK Dellagi

Abstract

Vipera lebetina fibrinogenase (VlF) was shown to render fibrinogen incoagulable and to solubilize fibrin. The fibrinogenolytic activity of this enzyme was found to be 33 mg fibrinogen/min/mg protein. The study of the specificity of this enzyme revealed that it has no effect on purified factor X, prothrombin and protein C and on the specific chromogenic substrates of their active form. Plasminogen was not activated by VlF but slightly degraded. We have also compared the effect of VlF and plasmin on fibrinogen and shown that these two enzymes have a different sites of cleavage. This enzyme inhibited human platelet aggregation on PRP initiated by ADP and collagen but was without effect on the aggregation of washed rabbit platelets using thrombin as agonist. Administration of VlF in rat did not show any necrosis or hemorrhage in treated rats organ's. We therefore, examined the thrombolytic activity of VlF in a rat model of venous thrombosis. Thrombus was produced in the posterior vena cava by injection of human fibrinogen and thrombin. Injection of 5 mg/Kg body weight showed an evident flow restoration after one hour and measurement of the fibrinogen level a decrease of about 30% after 3 hrs. VlF's action is not dependent on plasmi...Continue Reading

References

Jul 19, 1976·Biochimica Et Biophysica Acta·C Ouyang, T F Huang
Jan 1, 1991·Toxicon : Official Journal of the International Society on Toxinology·A GasmiK Dellagi
Jan 1, 1991·Toxicon : Official Journal of the International Society on Toxinology·E SiigurJ Siigur
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M S DennisR A Lazarus
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·B H ChaoJ M Maraganore
Jan 1, 1989·Thrombosis Research·T W WillisC W Miller
Sep 11, 1987·Biochimica Et Biophysica Acta·A MäharJ Siigur
Jul 1, 1970·British Journal of Haematology·N G ArdlieJ F Mustard
Jul 1, 1967·British Journal of Haematology·M P Esnouf, G W Tunnah
Oct 1, 1952·Archives of Biochemistry and Biophysics·T ASTRUP, S MULLERTZ

❮ Previous
Next ❯

Citations

May 11, 2005·Toxicon : Official Journal of the International Society on Toxinology·S Swenson, F S Markland
Dec 5, 1998·Toxicon : Official Journal of the International Society on Toxinology·F S Markland
Nov 22, 2005·Acta Pharmacologica Sinica·Xiu-Xia LiangGuang-Mei Yan
May 8, 2007·Toxicon : Official Journal of the International Society on Toxinology·L H GremskiS S Veiga
Jun 1, 2005·Toxicon : Official Journal of the International Society on Toxinology·Neville Marsh, Vaughan Williams
Feb 22, 2011·Toxicon : Official Journal of the International Society on Toxinology·Gargi MaityDebasish Bhattacharyya
May 13, 2015·International Journal of Biological Macromolecules·Sourav MajumdarAshis K Mukherjee
Jun 2, 2000·Protein Expression and Purification·H S Selistre-de-AraujoD H Souza
Feb 7, 2015·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Sourav MajumdarAshis K Mukherjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.